Last edition
News about "American Diabetes Association"
Novo Nordisk's Zenagamtide Delivers Up to 14.6 Percent Weight Loss in Type 2 Diabetes
Novo Nordisk’s investigational once-weekly therapy zenagamtide demonstrated significant A1C reductions and up to 14.6 percent weight loss in adults with Type 2 Diabetes in a phase 2 trial presented at ADA 2026. The strong results support advancement of zenagamtide into phase 3 clinical development.
American Diabetes Association | 08/06/2026 | By News Bureau
Pfizer's Berobenatide Shows Strong Phase 2b Results with Monthly Dosing
Pfizer’s GLP-1 receptor agonist berobenatide demonstrated robust efficacy and favorable tolerability in a Phase 2b trial, supporting once-monthly dosing.
American Diabetes Association | 08/06/2026 | By News Bureau
Pfizer's Monthly Injectable GLP-1 Shows Sustained Weight Loss
Pfizer’s phase-II (b) VESPER-III study demonstrated that its ultra-long-acting injectable GLP-1 receptor agonist PF-08653944 delivered statistically significant and sustained weight loss with monthly dosing, supporting its advancement into an expansive phase-III obesity programme planned for 2026.
American Diabetes Association | 04/02/2026 | By News Bureau | 309
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy